Scarica l'app Stockscreener
1.18
3.28%
-0.04
Dopo l'orario di chiusura:
1.21
0.03
+2.54%
Heartbeam Inc Borsa (BEAT) Ultime notizie
Heartbeam stock jumps after AI collaboration with Mount Sinai - MSN
HeartBeam's (BEAT) 'Significant Turning Point' Spotlighted in Recent Article - NewMediaWire
BEAT Stock Price, Quote & Chart | HEARTBEAM INC (NASDAQ:BEAT) - ChartMill
BEAT SEC FilingsHeartbeam Inc 10-K, 10-Q, 8-K Forms - Stock Titan
HeartBeam’s (NASDAQ: BEAT) ‘Significant Turning Point’ Spotlighted in Recent Article - TradingView
Sectors Review: Should value investors consider HeartBeam Inc2026 Analyst Calls & Real-Time Volume Analysis Alerts - baoquankhu1.vn
HeartBeam Reaches 'Significant Turning Point' After FDA Clearance - National Today
B. Riley Securities Initiates Coverage on HeartBeam (BEAT) with Buy Rating | BEAT Stock News - GuruFocus
B. Riley Securities Initiates HeartBeam(BEAT.US) With Buy Rating, Announces Target Price $4 - Moomoo
B.Riley initiates Heartbeam stock coverage with buy rating on FDA clearance - Investing.com
Aug Sentiment: What analysts say about HeartBeam Inc stock2026 Retail Activity & Low Drawdown Trading Strategies - baoquankhu1.vn
D. Boral Capital initiates Heartbeam stock coverage with buy rating By Investing.com - Investing.com India
This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
How Decentralized AI is Unlocking Value in Cardiac Diagnostics - Benzinga
D. Boral Capital initiates Heartbeam stock coverage with buy rating - Investing.com
HeartBeam (BEAT) Partners With Mount Sinai to Accelerate AI-ECG Development and Validation - Yahoo Finance
HeartBeam (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation - Digital Journal
HeartBeam (NASDAQ: BEAT) Secures FDA 510(k) Clearance for 12-Lead ECG Synthesis Software Following Successful Appeal - USA Today
HeartBeam (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software - USA Today
HeartBeam (BEAT) director receives 44,827-share stock option grant at $1.43 - Stock Titan
HeartBeam (BEAT) CFO receives stock options on 53,104 shares at $1.45 - Stock Titan
HeartBeam (BEAT) awards director Richard Ferrari 50,000 RSUs - Stock Titan
HeartBeam (BEAT) awards 41,380-share stock option grant to major holder - Stock Titan
HeartBeam (BEAT) director awarded 20,689 RSUs, holdings rise to 95,809 shares - Stock Titan
HeartBeam (BEAT) president receives 61,932-share stock option grant at $1.45 - Stock Titan
HeartBeam (BEAT) director receives 51,724 options at $1.43 exercise price - Stock Titan
HeartBeam (BEAT) director receives 17,241 RSUs in equity grant - Stock Titan
Director at HeartBeam (NASDAQ: BEAT) receives option grant for 51,724 shares - Stock Titan
HeartBeam (BEAT) president receives 55,172 stock options as equity grant - Stock Titan
Aug Opening: Can HeartBeam Inc outperform in the next rallyTrade Exit Report & Growth Oriented Trading Recommendations - baoquankhu1.vn
If You Invested $1,000 in Heartbeam Inc (BEAT) - Stock Titan
HeartBeam announces first patient enrollments in heart attack detection pilot study - MSN
HeartBeam : Earnings Documents - MarketScreener
HeartBeam (NASDAQ: BEAT) Collaborates With Mount Sinai to Advance AI-ECG Algorithm Development - USA Today
Aug Catalysts: Is HeartBeam Inc Equity Warrant benefiting from interest rate changesMarket Activity Report & Community Trade Idea Sharing - baoquankhu1.vn
Trend Recap: Is HeartBeam Inc a turnaround storyWeekly Trade Summary & Low Risk High Reward Ideas - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: HeartBeam (BEAT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
H.C. Wainwright reiterates Heartbeam stock rating on commercial progress By Investing.com - Investing.com India
H.C. Wainwright reiterates Heartbeam stock rating on commercial progress - Investing.com
Heartbeam Inc reports results for the quarter ended December 31Earnings Summary - TradingView
HeartBeam Shares Fall After Benchmark Maintains Speculative Buy Rating - marketscreener.com
Benchmark Maintains HeartBeam's Rating at Speculative Buy, Price Target is $8 - marketscreener.com
HeartBeam Shares Fall After Benchmark Downgrade - marketscreener.com
HeartBeam partners with Mount Sinai to advance AI-powered ECG technology - MSN
Benchmark Downgrades HeartBeam to Speculative Buy From Buy, Price Target is $8 - marketscreener.com
HeartBeam (NASDAQ: BEAT) Reports Q4 and Full-Year 2025 Results, Advances Commercialization and Clinical Development - USA Today
HeartBeam (NASDAQ: BEAT) Announces Commercial Partnership With ClearCardio - USA Today
HeartBeam (BEAT) Q4 2025 Earnings Call Transcript - AOL.com
HeartBeam to present at March investor conferences By Investing.com - Investing.com Nigeria
HeartBeam reports net loss of USD 5.3M in Q4 2025 - Medical Buyer
HeartBeam Earnings Call Balances Breakthroughs With Cash Risk - TipRanks
0.66%
3.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):